Theresa LaVallee, Ph.D. (Chair)

Dr. Theresa LaVallee is Chief Development Officer of Coherus BioSciences. She brings more than 25 years of drug discovery and development experience. Most recently, Dr. LaVallee was Vice President, Translational Medicine and Regulatory Affairs at the Parker Institute for Cancer Immunotherapy where she provided scientific leadership for clinical strategy for development of novel immuno-oncology therapies and helped establish the institute’s clinical, translational and regulatory organization. Previously, she held executive roles at Kolltan Pharma and Celldex Therapeutics. From 2008 – 2013, she was a member of the immuno-oncology team at AstraZeneca (MedImmune) developing checkpoint inhibitors and related diagnostics. She earned her Ph.D. from the University of California, Los Angeles and her bachelor’s degree from the University of California, Santa Barbara.